CLPT Form 4: CFO boosts holdings via 3,555-share option exercise

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. (CLPT) reported an insider equity transaction by its Chief Financial Officer, Danilo D'Alessandro. On 11/21/2025, he exercised stock options to acquire 3,555 shares of common stock at an exercise price of $8.10 per share and held all shares received, with no stock sold in connection with the transaction. Following this exercise, he beneficially owns 69,923 shares of ClearPoint Neuro common stock in direct ownership form.

The exercised options were part of a grant dated March 6, 2023, with vesting in three tranches: 20% on the first anniversary, 40% on the second, and 40% on the third. After the reported transaction, 12,082 stock options remain beneficially owned, with an expiration date of 03/06/2033.

Insider Trade Summary

3,555 shares exercised/converted

Mixed 2 txns

Insider D'Alessandro Danilo

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Stock Options (right to buy)	3,555	$0.00	--
Exercise	Common Stock	3,555	$8.10	$29K

Holdings After Transaction: Stock Options (right to buy) — 12,082 shares (Direct); Common Stock — 69,923 shares (Direct)

Footnotes (1)

1. Mr. D'Alessandro paid the exercise price for the option in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction. The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. The grant date is March 6, 2023.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

D'Alessandro Danilo

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/21/2025		M		3,555(1)	A	$8.1	69,923	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$8.1	11/21/2025		M			3,555(1)	(2)	03/06/2033	Common Stock	3,555	$0	12,082	D

Explanation of Responses:

1. Mr. D'Alessandro paid the exercise price for the option in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction.

2. The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. The grant date is March 6, 2023.

	/s/ Danilo D'Alessandro	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ClearPoint Neuro (CLPT) report in this Form 4?

The Form 4 reports that ClearPoint Neuro's Chief Financial Officer, Danilo D'Alessandro, exercised stock options on 11/21/2025 to acquire 3,555 shares of common stock at an exercise price of $8.10 per share.

Did the ClearPoint Neuro (CLPT) CFO sell any shares in this transaction?

No shares were sold. The filing states that Mr. D'Alessandro paid the exercise price in cash and has held all shares received upon exercise, with no stock sold in connection with this transaction.

How many ClearPoint Neuro (CLPT) shares does the CFO own after this Form 4 transaction?

After the option exercise, Mr. D'Alessandro beneficially owns 69,923 shares of ClearPoint Neuro common stock, reported as directly held.

What are the key terms of the stock options exercised by the ClearPoint Neuro (CLPT) CFO?

The derivative table shows stock options with an exercise price of $8.10 per share, originally granted on March 6, 2023. The options relate to 3,555 underlying shares of common stock and have an expiration date of 03/06/2033.

How do the ClearPoint Neuro (CLPT) CFO stock options vest?

The options vest in three stages based on the March 6, 2023 grant date: 20% of the total shares on the first anniversary, 40% on the second anniversary, and 40% on the third anniversary.

How many ClearPoint Neuro (CLPT) stock options does the CFO hold after this transaction?

Following the reported transaction, Mr. D'Alessandro beneficially owns 12,082 stock options on a direct basis, as disclosed in the derivative securities table.